ANDA 71443, held by Mylan. Amitriptyline Hydrochloride; Perphenazine.
As of Nov 16, 2026, ANDA 71443 (Perphenazine And Amitriptyline Hydrochloride), held by Mylan, was first approved by FDA on Nov 10, 1988, with 23 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Perphenazine and amitriptyline hydrochloride tablets are recommended for treatment of patients with moderate to severe anxiety and/or agitation and depressed mood, patients with depression in whom anxiety and/or agitation are severe, and patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate. Schizophrenic patients who have associated depressive symptoms should be considered for therapy with perphenazine and amitriptyline hydrochloride tablets.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 10, 1988 | Original application | Approved | None posted |
| Perphenazine And Amitriptyline Hydrochloride50MG;4MG · tablet;oral | Amitriptyline Hydrochloride; Perphenazine | Rx |
| Perphenazine And Amitriptyline Hydrochloride10MG;2MG · tablet;oral | Amitriptyline Hydrochloride; Perphenazine | Rx |
| Perphenazine And Amitriptyline Hydrochloride10MG;4MG · tablet;oral | Amitriptyline Hydrochloride; Perphenazine | Rx |
| Perphenazine And Amitriptyline Hydrochloride25MG;2MG · tablet;oral | Amitriptyline Hydrochloride; Perphenazine | Rx |
| Perphenazine And Amitriptyline Hydrochloride25MG;4MG · tablet;oral | Amitriptyline Hydrochloride; Perphenazine | Rx |
| Jun 24, 2025 | Supplement 44Labeling · Standard review | Approved | None posted |
| Jan 22, 2025 | Supplement 43Labeling · Standard review | Approved | None posted |
| Feb 23, 2017 | Supplement 32Labeling · Standard review | Approved | None posted |
| Apr 25, 2016 | Supplement 30Labeling · Standard review | Approved | None posted |
| Dec 13, 2014 | Supplement 29Labeling · Standard review | Approved | None posted |
| Jul 17, 2014 | Supplement 28Labeling · Standard review | Approved | |
| Sep 21, 2010 | Supplement 25Labeling | Approved | None posted |
| Jan 21, 2009 | Supplement 24Labeling | Approved | None posted |
| Oct 30, 2008 | Supplement 23Labeling | Approved | None posted |
| Nov 7, 2007 | Supplement 21Labeling | Approved | None posted |
| Jul 11, 2007 | Supplement 20Labeling | Approved | None posted |
| Jul 26, 2005 | Supplement 15Labeling | Approved | None posted |
| May 7, 2002 | Supplement 12Labeling | Approved | None posted |
| Feb 25, 1998 | Supplement 11Manufacturing | Approved | None posted |
| Feb 5, 1998 | Supplement 10Manufacturing | Approved | None posted |
| Feb 4, 1997 | Supplement 9Manufacturing | Approved | None posted |
| Jun 28, 1995 | Supplement 8Labeling | Approved | None posted |
| Oct 22, 1993 | Supplement 5Manufacturing | Approved | None posted |
| Oct 5, 1993 | Supplement 7Labeling | Approved | None posted |
| Oct 5, 1993 | Supplement 3Manufacturing | Approved | None posted |
| Sep 1, 1993 | Supplement 6Labeling | Approved | None posted |
| Jan 31, 1990 | Supplement 2Manufacturing | Approved | None posted |
| May 1, 1989 | Supplement 1Labeling | Approved | None posted |
| Nov 10, 1988 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters